Oncology Drug Pipeline Analysis Segment Is Witnessing Growth Due To Introduction Of Novel Cancer Treatments And Drugs
Oncology Drug Pipeline analysis |
The development of new drugs
requires hundreds of millions of dollars and takes 15-17 years. Along with
assessing the effectiveness of the drug, this analysis examines its safety and
likelihood of adverse reactions. The process is extremely costly and is
dependent on the successful approval of early-stage trials. Consequently, the
process of development and approval is complex and expensive. This is why it is
critical to use a reliable tool like Drug Pipeline Analysis to evaluate the
future development of a drug.
The
global oncology drug pipeline analysis is driven
by numerous factors, including increasing costs of therapies and the cost of
clinical trials. There are two main types of oncology pipelines. The first
category includes drugs that are still in development and have significant
market potential. The second category consists of cancer-related drugs. The
first segment includes products that are already available in the market. These
drugs are marketed in the US and abroad. Typically, the pharmaceutical industry
is split between North America and Europe. This area has the largest oncology
pipeline. The global oncology drug pipelines are fueled by research and
development, which is conducted by major pharmaceutical companies in these
regions.
The oncology field is witnessing the
rapid development of novel therapies for cancer. The U.S. Food and Drug Administration
approved 46 new molecular entities and biologic license applications in 2015,
with 16 of them being new cancer therapies. Such factors are propelling the
oncology drug pipeline analysis segment. This growth is expected to continue as
cancer-related treatments and new drugs are introduced in the region. There are
many companies that have successfully used oncology drug pipeline analysis to
identify the potential for new therapies. In November 2021, the U.S. Food and Drug
Administration granted approval to Carfilzomib (Kyprolis, Amgen, Inc.) plus
dexamethasone and daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen
Biotech, Inc.) for the treatment of adult patients suffering from relapsed multiple
myeloma.
Comments
Post a Comment